Pfizer, Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...
As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...
Pfizer will apply Triana Biomedicines’ target-first and proximity-first discovery platform to discover molecular glue degraders for unspecified “multiple” targets in oncology and several other ...
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
Guggenheim has raked in an estimated $172mn in fees from advising Pfizer on nearly $400bn of completed and attempted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback